CA3090204A1 - Pyrazole compounds and preparation thereof - Google Patents

Pyrazole compounds and preparation thereof Download PDF

Info

Publication number
CA3090204A1
CA3090204A1 CA3090204A CA3090204A CA3090204A1 CA 3090204 A1 CA3090204 A1 CA 3090204A1 CA 3090204 A CA3090204 A CA 3090204A CA 3090204 A CA3090204 A CA 3090204A CA 3090204 A1 CA3090204 A1 CA 3090204A1
Authority
CA
Canada
Prior art keywords
formula
compound
alkyl
haloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3090204A
Other languages
English (en)
French (fr)
Inventor
Sunil Sharma
Dinesh JANGID
Priyanka DHAKA
Siddharth MADHWAL
Bharat Kumar
Kapil Kumar
Rajdeep Anand
Anurag Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Anand Rajdeep
Dhaka Priyanka
Madhwal Siddharth
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anand Rajdeep, Dhaka Priyanka, Madhwal Siddharth, Myokardia Inc filed Critical Anand Rajdeep
Publication of CA3090204A1 publication Critical patent/CA3090204A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/122—Halides of copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3090204A 2018-02-01 2019-02-01 Pyrazole compounds and preparation thereof Pending CA3090204A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201811003855 2018-02-01
IN201811003859 2018-02-01
IN201811003859 2018-02-01
IN201811003855 2018-02-01
IN201711042921 2018-05-30
IN201711042921 2018-05-30
PCT/IN2019/050076 WO2019150392A1 (en) 2018-02-01 2019-02-01 Pyrazole compounds and preparation thereof

Publications (1)

Publication Number Publication Date
CA3090204A1 true CA3090204A1 (en) 2019-08-08

Family

ID=67478207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3090204A Pending CA3090204A1 (en) 2018-02-01 2019-02-01 Pyrazole compounds and preparation thereof

Country Status (14)

Country Link
US (1) US11873289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746434A4 (cg-RX-API-DMAC7.html)
JP (1) JP7402804B2 (cg-RX-API-DMAC7.html)
KR (1) KR102951622B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670184B (cg-RX-API-DMAC7.html)
AU (1) AU2019213854C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090204A1 (cg-RX-API-DMAC7.html)
IL (1) IL276410B2 (cg-RX-API-DMAC7.html)
MA (1) MA54677A (cg-RX-API-DMAC7.html)
MX (2) MX2020008151A (cg-RX-API-DMAC7.html)
MY (1) MY209060A (cg-RX-API-DMAC7.html)
SG (1) SG11202007328UA (cg-RX-API-DMAC7.html)
WO (1) WO2019150392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation
WO2025244956A1 (en) * 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007284386A (ja) 2006-04-18 2007-11-01 Kumiai Chem Ind Co Ltd 3−ピラゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する殺虫・殺ダニ・殺線虫剤
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN104703972B (zh) 2012-08-30 2017-05-31 拜耳农作物科学股份公司 3,5‑双(卤烷基)‑吡唑‑4‑甲酸衍生物的脱羧方法
WO2014089913A1 (zh) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
EP3063134B1 (en) 2013-11-01 2020-08-12 Srf Limited Process for the preparation of pyrazole derivatives
EP3015458A1 (en) 2014-11-03 2016-05-04 Bayer CropScience AG Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines
SG11201705928XA (en) 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
CN111132964A (zh) 2017-04-11 2020-05-08 欧瑞克制药公司 糖皮质激素受体调节剂
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation

Also Published As

Publication number Publication date
EP3746434A4 (en) 2021-11-17
IL276410B2 (en) 2024-09-01
IL276410B1 (en) 2024-05-01
MX2025003379A (es) 2025-05-02
MY209060A (en) 2025-06-18
JP2021512127A (ja) 2021-05-13
JP7402804B2 (ja) 2023-12-21
BR112020015692A2 (pt) 2020-12-08
AU2019213854C1 (en) 2023-12-14
US20210053940A1 (en) 2021-02-25
SG11202007328UA (en) 2020-08-28
KR102951622B1 (ko) 2026-04-13
AU2019213854A1 (en) 2020-09-03
CN111670184B (zh) 2026-07-10
MA54677A (fr) 2021-11-17
IL276410A (en) 2020-09-30
CN111670184A (zh) 2020-09-15
MX2020008151A (es) 2020-09-18
KR20200118025A (ko) 2020-10-14
AU2019213854B2 (en) 2023-06-15
WO2019150392A1 (en) 2019-08-08
US11873289B2 (en) 2024-01-16
EP3746434A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
US20220135533A1 (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
CN101321522B (zh) 环氧丁醇中间体的制备方法
EP2176269B1 (en) A method of manufacturing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-2-yl acetate (prasugrel)
JP6275881B2 (ja) デュオカルマイシンのプロドラッグを製造するための改良された方法
IL301897A (en) Preparation processes of 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN -7-YL)OXY)-benzonitrile
AU2019213854C1 (en) Pyrazole compounds and preparation thereof
CN115448971B (zh) 一种用于制备氟维司群的中间体及其制备方法
WO2022082337A1 (en) Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
TWI452040B (zh) 光酸發生劑之製造方法
EA044890B1 (ru) Пиразольные соединения и их получение
HK40027579A (en) Pyrazole compounds and preparation thereof
KR102436114B1 (ko) 신규한 이노토디올의 제조방법
JP2021512127A5 (cg-RX-API-DMAC7.html)
WO2005026176A1 (ja) 3−クロロメチル-3-セフェム誘導体の製造方法
KR102418153B1 (ko) 신규한 이노토디올의 제조방법
JP3534816B2 (ja) メチルチオベンゼン類の製造方法
JP2001506255A (ja) チアゾール類の製造
KR940006531B1 (ko) 피리딘 유도체의 제조방법
JP2009249357A (ja) 1−ビニル−4−[(4−ビニルフェニル)ジスルファニル]ベンゼン誘導体
TW201936597A (zh) 製備經取代之(1h-1,2,4-三唑-1-基)醇類之方法
JPH04283524A (ja) トリフルオロメチル置換芳香族化合物の製造法
JPH0217550B2 (cg-RX-API-DMAC7.html)
JP2004115476A (ja) (r)−3−ハロゲノ−2−メチルプロパノールの製造方法
WO2017159669A1 (ja) フェノキシエタノール誘導体の製造方法
JPH06271546A (ja) イミダゾリジン誘導体の製造法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240118

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250207

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20260602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260602

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260611

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260615

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260615